Literature DB >> 16937146

Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging.

Bei Ding1, Hua Wei Ling, Ke Min Chen, Hong Jiang, Yan Bo Zhu.   

Abstract

INTRODUCTION: Regional cerebral blood volume (rCBV) and permeability surfaces (rPS) permit in vivo assessment of glioma microvasculature, which provides quite important pathophysiological information in grading gliomas. The aim of our study was to simultaneously examine rCBV and rPS in glioma patients to determine their correlation with histological grade using CT perfusion imaging.
METHODS: A total of 22 patients with gliomas underwent multislice CT perfusion imaging preoperatively. Low-grade and high-grade groups were categorized corresponding to WHO grade II gliomas and WHO grade III or IV gliomas, respectively, as determined by histopathological examination. rCBVs and rPSs were obtained from regions of maximal abnormality in tumor parenchyma on CBV and PS color perfusion maps. Perfusion parameters were compared using the Kruskal-Wallis test in order to evaluate the differences in relation to tumor grade. The Pearson coefficients of rCBV and rPS for each tumor grade were assessed using SPSS 13.0 software.
RESULTS: rCBV and rPS provided significant P-value in differentiating glioma grade (low-grade gliomas 3.28+/-2.01 vs 2.12+/-3.19 ml/100 g/min, high-grade gliomas 8.87+/-4.63 vs 12.11+/-3.18 ml/100 g/min, P<0.05). Receiver operating characteristic (ROC) curves revealed better specificity and sensitivity in PS than in CBV for glioma grade. A significant correlation between rCBV and rPS was observed in high-grade gliomas (r=0.684). rCBVs in oligodendrogliomas were higher than in other low-grade gliomas, whereas their rPS values did not show a parallel difference.
CONCLUSION: Perfusion CT provides useful information for glioma grading and might have the potential to significantly impact clinical management and follow-up of cerebral gliomas.

Entities:  

Mesh:

Year:  2006        PMID: 16937146     DOI: 10.1007/s00234-006-0120-1

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  33 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  The role of blood-brain barrier permeability in brain tumor imaging and therapeutics.

Authors:  James M Provenzale; Srinivasan Mukundan; Mark Dewhirst
Journal:  AJR Am J Roentgenol       Date:  2005-09       Impact factor: 3.959

Review 3.  Tumoral vascularity as a prognostic factor in cancer.

Authors:  N Weidner; J Folkman
Journal:  Important Adv Oncol       Date:  1996

4.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.

Authors:  Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

5.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases.

Authors:  C Daumas-Duport; P Varlet; M L Tucker; F Beuvon; P Cervera; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 6.  Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review.

Authors:  A Amoroso; F Del Porto; C Di Monaco; P Manfredini; A Afeltra
Journal:  Eur Rev Med Pharmacol Sci       Date:  1997 Jan-Jun       Impact factor: 3.507

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

8.  Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results.

Authors:  Ji Hoon Shin; Ho Kyu Lee; Byung Duk Kwun; Jin-Suh Kim; Weechang Kang; Choong Gon Choi; Dae Chul Suh
Journal:  AJR Am J Roentgenol       Date:  2002-09       Impact factor: 3.959

Review 9.  Advances in the biology of astrocytomas.

Authors:  Abhijit Guha; Joydeep Mukherjee
Journal:  Curr Opin Neurol       Date:  2004-12       Impact factor: 5.710

10.  Reproducibility of quantitative CT perfusion imaging.

Authors:  J H Gillard; N M Antoun; N G Burnet; J D Pickard
Journal:  Br J Radiol       Date:  2001-06       Impact factor: 3.039

View more
  26 in total

Review 1.  Clinical applications of susceptibility weighted MR imaging of the brain - a pictorial review.

Authors:  Bejoy Thomas; Sivaraman Somasundaram; Krishnamoorthy Thamburaj; Chandrasekharan Kesavadas; Arun Kumar Gupta; Narendra K Bodhey; Tirur Raman Kapilamoorthy
Journal:  Neuroradiology       Date:  2007-10-11       Impact factor: 2.804

2.  Quantitative accuracy of computed tomography perfusion under low-dose conditions, measured using a hollow-fiber phantom.

Authors:  Kazufumi Suzuki; Hiroyuki Hashimoto; Eiji Okaniwa; Hiroshi Iimura; Shingo Suzaki; Kayoko Abe; Shuji Sakai
Journal:  Jpn J Radiol       Date:  2017-04-27       Impact factor: 2.374

3.  Comparison between CT and MR in perfusion imaging assessment of high-grade gliomas.

Authors:  M De Simone; C F Muccio; S M Pagnotta; G Esposito; A Cianfoni
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

4.  Grading of oligodendroglial tumors of the brain with apparent diffusion coefficient, magnetic resonance spectroscopy, and dynamic susceptibility contrast imaging.

Authors:  Muhammad Atif Naveed; Pradeep Goyal; Ajay Malhotra; Xiang Liu; Sonali Gupta; Manisha Mangla; Rajiv Mangla
Journal:  Neuroradiol J       Date:  2018-02-22

5.  Perfusion computed tomography assessments of peri-enhancing brain tissue in high-grade gliomas.

Authors:  A Stecco; F Fabbiano; P Amatuzzo; E Cignini; M Brambilla; L Masini; M Krengli; A Carriero
Journal:  Radiol Med       Date:  2012-08-08       Impact factor: 3.469

6.  Survival prediction in high-grade gliomas using CT perfusion imaging.

Authors:  Timothy Pok Chi Yeung; Yong Wang; Wenqing He; Benedetta Urbini; Roberta Gafà; Linda Ulazzi; Slav Yartsev; Glenn Bauman; Ting-Yim Lee; Enrico Fainardi
Journal:  J Neurooncol       Date:  2015-04-11       Impact factor: 4.130

7.  Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade.

Authors:  R Jain; S K Ellika; L Scarpace; L R Schultz; J P Rock; J Gutierrez; S C Patel; J Ewing; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-17       Impact factor: 3.825

8.  Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery.

Authors:  Koichi Mitsuya; Yoko Nakasu; Satoshi Horiguchi; Hideyuki Harada; Tetsuo Nishimura; Etsuro Bando; Hiroto Okawa; Yoshihiro Furukawa; Tatsuo Hirai; Masahiro Endo
Journal:  J Neurooncol       Date:  2010-01-08       Impact factor: 4.130

9.  Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?

Authors:  Rajan Jain; Shehanaz Ellika; Norman L Lehman; Lisa Scarpace; Lonni R Schultz; Jack P Rock; Mark Rosenblum; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2009-10-15       Impact factor: 4.130

10.  Role of perfusion CT in glioma grading and comparison with conventional MR imaging features.

Authors:  S K Ellika; R Jain; S C Patel; L Scarpace; L R Schultz; J P Rock; T Mikkelsen
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-24       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.